HANSHOW
28.2.2024 10:59:29 CET | Business Wire | Press release
Hanshow, a leader in retail technology innovation, today unveiled a series of Green Store Solutions, designed to accelerate the retail industry towards a sustainable future. Complementing this new product, Hanshow has also released a comprehensive Green Digitalization Report alongside tech partners Microsoft, Intel, and E Ink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223583112/en/
Hanshow at EuroCIS 2024 (Photo: Business Wire)
The Polaris Pro Electronic Shelf Labels (ESL) series stands out with its high screen-to-body ratio, multi-color display capabilities, and user-replaceable battery system designed for longevity, embodying Hanshow's commitment to sustainability. This advanced ESL solution is set to reduce paper waste, improve pricing accuracy, and enhance the overall aesthetic of modern retail environments.
Building on the innovative leadership of the Polaris Pro, Hanshow's Green Store Solutions extend beyond ESLs to include dynamic in-store marketing and AI-driven solutions. These innovations optimize store performance through targeted promotions, precise inventory management, and real-time data insights, facilitating smarter, greener operations.
To push the boundaries of what is possible in retail further, Hanshow integrates GenAI technology into its digital retail Solutions, enhancing operational efficiency and customer experiences. This adoption of GenAI simplifies complex processes and decision-making, making retail operations more efficient and intuitive. GenAI serves as an assistant to both store associates and customers, enabling easier navigation, personalized shopping experiences, and enhanced staff productivity.
Hanshow’s authoritative Green Digitalization Report, highlighting the dual benefits of digitalization and sustainability. The report, produced in cooperation with Microsoft, Intel, and E Ink, offers a deep dive into how retailers can use green digitalization as a double engine for growth, marrying eco-efficiency with cutting-edge innovation.
"Hanshow is proud to be at the forefront of the movement towards a greener, more digital future for retail," said Liangyan Li, SVP and Head of Global Sales at Hanshow. "With the introduction of the Polaris Pro series and our comprehensive Green Store Solutions, including our pioneering work on GenAI, we are paving the way for retailers to operate sustainably without compromising on customer satisfaction or operational excellence."
To further promote the many exciting ways in tech technology is laying a stronger foundation for sustainability in the retail industry, Hanshow’s Green Digitalization Report outlines actionable strategies to integrate sustainability into core business operations through innovative technologies. The report was released jointly with important contributions from industry partners such as Microsoft, Intel, and E Ink, and emphasizes myriad ways in which new technological advancements in AI, IOT, and data-driven decision-making will optimize management, reduce resource waste and store costs, improve associates’ work productivity and job satisfaction, and more accurately track and adjust customer experiences both in-store and online, all while helping retailers to meet sustainability targets.
Retailers eager to explore the Polaris Pro series, the suite of Green Store Solutions, and the findings of the Green Digitalization Report are invited to connect with Hanshow's team. Demonstrations and consultations are available to showcase how these initiatives can be seamlessly incorporated into existing retail frameworks.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223583112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom